Trust Center
Medical Cooling · Trust Center · Last reviewed 17 October 2026
Trust should be reviewable.
This page brings the main trust, compliance and evidence controls for MedicalCooling.com into one place. AIRCHILL is a development-stage medical-technology project: no CE mark, no FDA clearance, not for patient use, and no established AIRCHILL clinical outcome benefit is claimed.
Privacy
Optional analytics, marketing and external media are disabled by default in the active Site Agent consent runtime. Global Privacy Control is recognized for relevant marketing / sale-share opt-outs. The production browser audit checks that optional third-party requests do not occur before consent or after Reject.
Accessibility
WCAG 2.2 Level AA is the engineering target. Automated Chromium + axe checks cover core pages, keyboard focus, reduced motion, image alternatives, contrast and consent controls. We do not represent that every legacy page or document is independently certified.
Regulatory status & claim governance
Product, mechanism, clinical-context, regulatory and market-access statements are intentionally separated. Planning assumptions are not presented as approvals, established efficacy, forecasts or guarantees. Regulatory classification and US pathway remain development workstreams.
Positive, testable development framing: editorial and agent-generated content should lead with the evidence already observed and the next study goal. Unresolved development questions are phrased prospectively — for example, “we plan to test and size the early-cooling effect” — rather than with discouraging shorthand such as “not shown” when the accurate status is “next clinical validation target.” The evidence boundary belongs in the same paragraph. Neutral and negative studies remain visible and are used to improve population, route, timing, dose, safety and endpoint design; animal and subgroup signals are never relabelled as established human efficacy. English is the scientific source of truth: substantive evidence, claim and study-goal changes are made on the English source pages first; localized pages should follow the versioned English source rather than develop an independent evidence narrative.
Evidence & data sources
Public pages distinguish established literature, AIRCHILL-specific evidence, derived values, transferred assumptions and explicit data gaps. Source registers and model assumptions are published where possible so readers can trace the basis of material statements.
Security & operational controls
- WordPress security and abuse-prevention controls are active.
- Production changes use a backup-and-rollback workflow; a complete UpdraftPlus backup includes database, plugins, themes and uploads.
- Transaction-sensitive investor documents are not published in the public data room.
- Automated production checks are designed to catch visible CSS leakage, consent regressions, accessibility failures and missing status disclosures before they are treated as release-ready.
Change history
- 15 August 2026: accessibility contrast/link remediation; simplified 10-second homepage status layer; roadmap states; investor closing-readiness matrix; segmented partnership CTAs; Trust Center and stronger production release gates.
- 14 August 2026: homepage and investor-data-room CSS display defects repaired; development-status banners added; compact consent surface; legal/privacy/accessibility footer access; Investor Snapshot published; browser privacy/accessibility audit introduced.
Legal & contact
Legal Notice / Impressum · Privacy Policy · Cookie & Privacy Choices · Accessibility · Disclaimer
Questions about the project, evidence, privacy, accessibility or investor diligence can be sent through the Medical Cooling contact page.
Translation governance
MedicalCooling.com now uses a site-wide full-translation policy across all 17 active locales: English, German, Dutch, Italian, Spanish, Portuguese, French, Polish, Czech, Hungarian, Danish, Swedish, Simplified Chinese, Traditional Chinese, Japanese, Korean and Arabic (Qatar). The full-translation policy is a buildout target, not a claim of completed coverage: not every published source page has all active-language versions yet. Missing translations must remain visible in the coverage register and must not be presented as complete.
Translation freshness is governed by the live Site Agent source hash and version. A localized page should be treated as current only after its translated title, excerpt, content, links, invariant data and essential page functionality have been checked against the live source. A stored CURRENT version flag is a workflow record, not by itself proof of complete linguistic or functional parity. QA preserves URLs and links, study identifiers such as NCT numbers, FDA and other regulatory identifiers, numbers, units, dates, named standards, protocol codenames, dataset values and evidence strength. Translations must never strengthen medical, regulatory or efficacy claims.
Translation coverage check — 17 October 2026: WordPress lists 321 published pages across 17 active locales. The translation registry contains 15 clusters. All 16 localized Trust Center pages have now been published, but their first editions were abridged and are not proof of complete translation. The translation registry and language navigation must be checked against their current URLs and substantive content. Numerous clinical-development, research, market-access and country pages still lack complete 17-locale coverage. The Germany EMS reimbursement cluster has a German REVIEW_REQUIRED entry pending reconciliation of its expanded district data with the English source. The earlier 78-cluster / 1,326-page figure was a proposed coverage target, not a completed release. Existing English pages normally remain the source; German-only EMS and country deep dives may retain German as their source. New sources must be registered and reviewed for evidence, medical claims, links and translation parity before being marked current.
AIRCHILL remains development-stage, without CE marking or FDA clearance and not for patient use. ATHLETE-AIRWAY is not part of the AIRCHILL study programme; the active airway programme is COLD-DOSE and AIRCHILL-FIRST.